Loading...

Viking Therapeutics

DB:1VT
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1VT
DB
$635M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Viking Therapeutics has significant price volatility in the past 3 months.
1VT Share Price and Events
7 Day Returns
-13.4%
DB:1VT
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
107.2%
DB:1VT
-10.6%
DE Biotechs
-6.2%
DE Market
1VT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Viking Therapeutics (1VT) -13.4% - - 107.2% 478.7% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 1VT outperformed the Biotechs industry which returned -10.6% over the past year.
  • 1VT outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
1VT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Viking Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Viking Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €7.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Viking Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Viking Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1VT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.38
NasdaqCM:VKTX Share Price ** NasdaqCM (2019-04-18) in USD $8.82
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Viking Therapeutics.

DB:1VT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VKTX Share Price ÷ EPS (both in USD)

= 8.82 ÷ -0.38

-23.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Viking Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Viking Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Viking Therapeutics's expected growth come at a high price?
Raw Data
DB:1VT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -23.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
-26.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Viking Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Viking Therapeutics's assets?
Raw Data
DB:1VT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.15
NasdaqCM:VKTX Share Price * NasdaqCM (2019-04-18) in USD $8.82
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:1VT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VKTX Share Price ÷ Book Value per Share (both in USD)

= 8.82 ÷ 4.15

2.13x

* Primary Listing of Viking Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Viking Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Viking Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Viking Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Viking Therapeutics expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-26.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Viking Therapeutics expected to grow at an attractive rate?
  • Unable to compare Viking Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Viking Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Viking Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1VT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1VT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts -26.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1VT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1VT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 43 -125 -104 3
2022-12-31 0 -71 -78 6
2021-12-31 0 -25 -58 8
2020-12-31 0 -42 -46 10
2019-12-31 0 -32 -33 10
DB:1VT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -19 -22
2018-09-30 -20 -21
2018-06-30 -18 -20
2018-03-31 -17 -19
2017-12-31 -15 -21
2017-09-30 -13 -20
2017-06-30 -13 -18
2017-03-31 -12 -16
2016-12-31 -11 -15
2016-09-30 -12 -16
2016-06-30 -13 -17
2016-03-31 -11 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Viking Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Viking Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1VT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Viking Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1VT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.27 -0.40 -1.90 4.00
2022-12-31 -0.96 -0.40 -1.60 6.00
2021-12-31 -0.76 -0.50 -1.06 7.00
2020-12-31 -0.57 -0.43 -0.69 9.00
2019-12-31 -0.44 -0.34 -0.55 9.00
DB:1VT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.38
2018-09-30 -0.44
2018-06-30 -0.53
2018-03-31 -0.60
2017-12-31 -0.79
2017-09-30 -0.86
2017-06-30 -0.84
2017-03-31 -0.83
2016-12-31 -0.90
2016-09-30 -1.29
2016-06-30 -1.71
2016-03-31 -2.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Viking Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Viking Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Viking Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Viking Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Viking Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Viking Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Viking Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Viking Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Viking Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Viking Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1VT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -22.06 7.12 19.04
2018-09-30 -20.91 6.57 16.98
2018-06-30 -20.41 6.09 14.76
2018-03-31 -18.91 5.65 13.26
2017-12-31 -20.58 5.33 13.74
2017-09-30 -20.14 5.03 13.36
2017-06-30 -17.85 4.96 12.00
2017-03-31 -16.37 4.90 10.65
2016-12-31 -14.73 4.85 9.00
2016-09-30 -16.18 5.16 9.57
2016-06-30 -17.11 5.78 9.98
2016-03-31 -21.28 6.10 8.71
2015-12-31 -23.40 5.03 6.97
2015-09-30 -16.92 3.84 3.89
2015-06-30 -12.45 2.42 2.17
2015-03-31 -27.37 1.41 22.31
2014-12-31 -21.88 1.24 22.22
2014-09-30 -23.33 1.07 22.08
2014-06-30 -23.13 0.75 21.30
2014-03-31 -0.37 0.25 0.06
2013-12-31 -0.15 0.09 0.01
2012-12-31 -0.44 0.16 0.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Viking Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Viking Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Viking Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Viking Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Viking Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Viking Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Viking Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Viking Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Viking Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Viking Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Viking Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Viking Therapeutics Company Filings, last reported 3 months ago.

DB:1VT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 297.75 0.00 301.52
2018-09-30 302.05 0.00 304.16
2018-06-30 140.36 0.00 142.17
2018-03-31 72.63 3.72 77.47
2017-12-31 13.46 3.45 20.58
2017-09-30 2.23 3.18 9.84
2017-06-30 6.59 3.05 12.08
2017-03-31 7.55 3.71 12.31
2016-12-31 8.04 3.27 13.15
2016-09-30 10.22 2.83 14.62
2016-06-30 12.79 2.38 17.20
2016-03-31 5.77 3.14 11.25
2015-12-31 8.72 2.15 14.10
2015-09-30 13.27 1.91 17.49
2015-06-30 17.39 1.67 21.66
2015-03-31 -27.84 1.74 0.33
2014-12-31 -22.13 1.57 0.76
2014-09-30
2014-06-30 -23.26 0.61 0.89
2014-03-31 -0.48 0.29 0.08
2013-12-31 -0.25 0.28 0.18
2012-12-31 -0.11 0.04
  • Viking Therapeutics has no debt.
  • Viking Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Viking Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Viking Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 23.6% each year.
X
Financial health checks
We assess Viking Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Viking Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Viking Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Viking Therapeutics dividends.
If you bought €2,000 of Viking Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Viking Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Viking Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1VT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1VT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Viking Therapeutics has not reported any payouts.
  • Unable to verify if Viking Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Viking Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Viking Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Viking Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Viking Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Viking Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Viking Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brian Lian
COMPENSATION $804,733
AGE 52
TENURE AS CEO 6.6 years
CEO Bio

Dr. Brian Lian, Ph.D., has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian serves as Director of Seelos Therapeutics, Inc. He served as Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, Inc., Research Division from 2012 to 2013. He served as a Managing Director and Senior Biotechnology Analyst of Healthcare Group of Global Hunter Securities, LLC, Research Division from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, from 2008 to 2011. Dr. Lian has over 15 years of experience in the biotechnology and financial services industries. He served as an Equity Analyst of BNP Paribas Fortis, Research Division. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, from 2006 to 2008. He served as Research Analyst at CIBC World Markets Corp., American Research Division. He served as Senior Biotechnology Analyst at Oppenheimer & Co. Inc., Research Division. He served as Senior Research Analyst at CIBC World Markets Inc., Research Division. He served as Senior Research Analyst at Fortis Securities Inc., Research Division. He served as Managing Director of Healthcare Research at Meridian Equity Partners, Inc., Research Division and Meridian Equity Partners, Inc. He served as Research Scientist at Amgen Inc. He joined Meridian Equity Partners, Inc. from The Agave Group LLC, a New York-based research boutique and has 7 years of experience covering the healthcare sector. From 2003 to 2008, he covered biotechnology and specialty pharmaceutical companies. He served as Senior Research Analyst for Biotechnology at Fortis Bank. In 2008, he founded The Agave Group, a healthcare research platform to serve portfolio managers, analysts, traders and corporate clients. He was a Research Scientist at Microcide Pharmaceuticals, where he worked in collaboration with Pfizer to identify novel classes of antibiotics. He worked at The Agave Group LLC. He served as Interim Chairman of Viking Therapeutics, Inc. until June 4, 2015. He has been a Director at Viking Therapeutics, Inc. since September 24, 2014. He served as an Executive Director at Oppenheimer & Co. Inc., Research Division and at CIBC World Markets Inc., Research Division. He co-authored research in organic chemistry, medicinal chemistry, biochemistry and chemical physics and contributed to texts in organic and advanced organic chemistry. Dr. Lian received his MS and Ph.D. in Organic Chemistry from The University of Michigan, an M.B.A. in Finance and Accounting from Indiana University and a B.A. in Chemistry from Whitman College.

CEO Compensation
  • Brian's compensation has increased whilst company is loss making.
  • Brian's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Viking Therapeutics management team in years:

3.5
Average Tenure
53
Average Age
  • The tenure for the Viking Therapeutics management team is about average.
Management Team

Brian Lian

TITLE
President
COMPENSATION
$805K
AGE
52
TENURE
6.6 yrs

Michael Morneau

TITLE
Vice President of Finance & Administration
COMPENSATION
$453K
AGE
53

Amy Broidrick

TITLE
Senior Vice President of Corporate Development
TENURE
2.3 yrs

Hiroko Masamune

TITLE
Chief Development Officer
AGE
61
TENURE
4.8 yrs

Marianne Mancini

TITLE
Senior Vice President of Clinical Operations
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Viking Therapeutics board of directors in years:

4.9
Average Tenure
58.5
Average Age
  • The tenure for the Viking Therapeutics board of directors is about average.
Board of Directors

Lawson MacArtney

TITLE
Chairman
COMPENSATION
$97K
AGE
61
TENURE
3.8 yrs

Brian Lian

TITLE
President
COMPENSATION
$805K
AGE
52
TENURE
6.6 yrs

J. Singleton

TITLE
Director
COMPENSATION
$70K
AGE
66
TENURE
4.9 yrs

Stephen Webster

TITLE
Director
COMPENSATION
$72K
AGE
57
TENURE
4.9 yrs

Charlie Rowland

TITLE
Director
COMPENSATION
$50K
AGE
60
TENURE
1.8 yrs

Matt Foehr

TITLE
Director
COMPENSATION
$46K
AGE
45
TENURE
4.9 yrs

David Bullough

TITLE
Scientific Advisor

Alan Cherrington

TITLE
Scientific Advisor

Zan Fleming

TITLE
Scientific Advisor

Scott Hecker

TITLE
Scientific Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Sep 18 Sell Ligand Pharmaceuticals Incorporated Company 25. Sep 18 25. Sep 18 -262,881 €16.27 €-4,276,595
31. May 18 Sell Michael Morneault Individual 31. May 18 31. May 18 -21,551 €7.93 €-170,980
31. May 18 Buy J. Singleton Individual 31. May 18 31. May 18 9,500 €8.42 €79,990
31. May 18 Buy Charles Rowland Individual 29. May 18 29. May 18 30,000 €4.47 €133,979
31. May 18 Buy Stephen Webster Individual 29. May 18 29. May 18 8,000 €4.51 €36,102
31. May 18 Buy Lawson MacArtney Individual 29. May 18 29. May 18 47,965 €4.52 €216,660
X
Management checks
We assess Viking Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Viking Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company’s lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.

Details
Name: Viking Therapeutics, Inc.
1VT
Exchange: DB
Founded: 2012
$564,894,474
72,027,657
Website: http://www.vikingtherapeutics.com
Address: Viking Therapeutics, Inc.
12340 El Camino Real,
Suite 250,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VKTX Common Stock Nasdaq Capital Market US USD 29. Apr 2015
DB 1VT Common Stock Deutsche Boerse AG DE EUR 29. Apr 2015
LSE 0VQA Common Stock London Stock Exchange GB USD 29. Apr 2015
Number of employees
Current staff
Staff numbers
17
Viking Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.